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A B S T R A C T
BACkgRound Cytochrome P450 2D6 (CYP2D6) has been linked to one of four phe-
notypes: a) ultra-rapid metabolizers (UM), with multiple gene copies; b) extensive me-
tabolizers (EM), with a single wild type gene copy, considered normal; c) intermediate 
metabolizers (IM), with decreased enzymatic activity; and d) poor metabolizers (PM) 
with no detectable enzymatic activity. By altering the drug dose-plasma concentration 
relationship, these differences may lead to severe toxicity and/or therapeutic failure.
oBjeCTiveS The aim of this study was to determine the correlation between CYP2D6 
polymorphisms and both efficacy and magnitude of adverse reactions of flecainide, a 
class IC antiarrhythmic agent. 
MeThodS Patients with lone atrial fibrillation (AF) were enrolled in a 2-groups pro-
spective study: patients started on flecainide at the initial visit, then were followed 
up at 3 and 6 months intervals (group 1) or exhibited AF recurrences on flecainide, 
defined as treatment failure (group 2). Data about recurrence of AF, side effects, 
and demographics were collected. Genotyping was performed using AmpliChipTM 
CYP450.
ReSulTS A total of 26 lone AF patients were enrolled (12 in group 1, and 14 in group 
2). The mean age was 47± 10.8 years and 56.2 ± 10.8 years respectively. Among the 
analyzed phenotypes, the following distribution was found: 1/26 (3.8%) UM, 19/26 
(73%) EM, 5/26 (19%) IM, 1/26 (3.8%) PM.
ConCluSionS In this small series of patients with lone atrial fibrillation, most pa-
tients were found to be extensive metabolizers of flecainide. There was no statistically 
significant correlation between the patients’ genotype and flecainide efficacy / side 
effects. 
i n T R o d u C T i o n
Flecainide is a sodium channel blocker from the class IC group in the Vaughan-
Williams classification of antiarrhythmic drugs. Flecainide is metabolized by cyto-
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chrome P450 (CYP) 2D6 in the liver and is excreted by the 
kidneys.1,2 The pH-dependent renal excretion of flecainide is a 
major route of its elimination.3 In patients with impaired renal 
function or with elevated urinary pH, flecainide’s elimination 
is dominated by hepatic metabolism.4 The hepatic metabolism 
of flecainide is mediated mainly by cytochrome P450 (CYP) 
2D6, which catalyses the conversion of flecainide to m-o-
dealkylated flecainide (MODF), with subsequent oxidation 
to m-o-dealkylated lactam.5 Flecainide is 10-fold more po-
tent than MODF, while the m-o-dealkylated lactam has no 
antiarrhythmic activity.3 
CYP2D6 has been linked to one of the following four phe-
notypes: a) ultra-rapid metabolizers (UM), with multiple gene 
copies; b) extensive metabolizers (EM), with a single wild type 
gene copy, considered normal; c) intermediate metabolizers 
(IM), with decreased enzymatic activity; and d) poor metabo-
lizers (PM) with no detectable enzymatic activity. By altering 
the drug dose-plasma concentration relationship, these differ-
ences may lead to severe toxicity and/or therapeutic failure in 
some patients.6,7 Tailoring the flecainide dose to the patient’s 
genetic profile will enable clinicians to achieve optimal plasma 
concentration and avoid drug toxicity.
The aim of the present study was to determine the correla-
tion between CYP2D6 polymorphisms and both efficacy and 
magnitude of adverse reactions of flecainide in patients with 
lone atrial fibrillation (AF).
M e T h o d S
M A T e R i A l S  A n d  S u B j e C T S
The study population included 26 patients with lone AF 
who were referred to the Assaf Harofeh Medical Center out-
patient clinic from October 1, 2009 to April 1, 2010 (Table 
1). The patients were all residents of the State of Israel and 
belonged to different ethnic groups. Thirteen patients were 
from Central or Eastern Europe, while the other 13 were 
from Western Europe, the Middle East or North Africa. The 
patients were 18 to 68 years old and had structurally normal 
hearts defined by echocardiography. Each patient had a history 
of recurrent AF more than 3 times a year prior to the initial 
visit. The exclusion criteria included coronary artery disease, 
high degree atrioventricular nodal block, presence of a perma-
nent pacemaker, current use of antiarrhythmic drugs, a body 
mass index greater than 26, glucose blood levels greater than 
130 mg% or the use of hypoglycemic drugs, chronic obstructive 
pulmonary disease or asthma, obstructive sleep apnea, prior 
stroke, renal failure with creatinine greater than 1.2 mg% and 
glomerular filtration rate <40 ml/min, elevated liver function 
tests 3 times the normal values, abnormal thyroid function 
tests, abnormal coagulation tests, neoplasm on medications, 
psychiatric diagnosis on medications, pregnancy and history 
of non-compliance. 
Blood samples for genotyping were collected at the initial 
visit prior to initiation of any treatment. Genotyping was per-
formed using AmpliChipTM CYP450 (Roche Molecular Diag-
nostics, Alameda, CA, USA). AmpliChipTM CYP450 contains 
more than 15,000 different oligonucleotide probes to analyze 
both the sense and the antisense strands of an amplified target 
DNA sample and provides comprehensive coverage of gene 
variations that play a role in the metabolism of approximately 
25% of all prescription drugs. The chip genotypes accurately 
>99% of the world’s population.8-15
The patients were enrolled in a 2-groups prospective study: 
patients started on flecainide 100 mg twice a day at the initial 
visit, then were followed up at 3 and 6 months intervals (group 
1) or exhibited AF recurrences within one week of treatment 
with flecainide, defined as treatment failure (group 2). Data 
about recurrence of AF, side effects, and demographics were 
collected. A 12-lead ECG was performed at each visit. A 
Holter monitor was performed prior to each visit. The dose 
of flecainide was increased to 150 mg twice a day in patients 
who had AF recurrence and decreased to 50 mg twice a day in 
patients who developed side-effects. If side-effects persisted, 
flecainide was discontinued. The patients who failed flecainide 
therapy were enrolled in group 2 and were not seen for further 
follow-up. The study protocol was approved by the ethical com-
mittee of Assaf Harofeh Medical Center. Written informed 
consent was obtained from each patient. 
S T A T i S T i C A l  A n A ly S i S
Data are expressed as percentages or mean ± standard 
deviation. The Chi-square test was used for the categorical 
variables and the independent sample t–test for the con-
tinuous variables. Statistical analysis was performed using an 
SPSS version 13 software. A p value of <0.05 was considered 
statistically significant.
R e S u l T S
A total of 26 lone AF patients were enrolled (12 in group 
1, and 14 in group 2). The mean age was 47± 10.8 years old 
in group 1 and significantly higher at 56.2 ± 10.8 years old 
in group 2. The rest of demographics parameters are sum-
marized in Table 1. Of the analyzed phenotypes 1/26 (3.8%) 
patients was found to be UM , 19/26 (73%) EM, 5/26 (19%) 
IM and 1/26 (3.8%) PM. The CYP2D6 allele frequencies are 
detailed in Table 2. 
Flecainide was found to be effective (no AF recurrence 
during the follow up period) and without side-effects in 14 /26 
(53.8%) patients, effective with side-effects in 3/26 (11.5%) pa-
tients, ineffective without side-effects in 5/26 (19.2%) patients, 
and ineffective with side-effects in 1/26 (3.8%) patients. The 
3 patients in whom flecainide was effective with side-effects 
had the following adverse events: one had abnormal liver 
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function tests, one had bradycardia and one had headaches 
which subsided when the flecainide dose was decreased from 
200 mg to 100 mg daily. The patients in whom flecainide was 
ineffective and had side-effects complained of weakness and 
the drug had to be discontinued. Three (11.5%) patients were 
noncompliant with medical regimen. No statistically significant 
correlation was found between gender and drug efficacy as 
well as between the CYP2D6 genotype and drug efficacy or 
side-effects. The number of patients in the ultra-rapid me-
tabolizers group (UM) and in the poor metabolizers group 
(PM) was small (one patient in each group) and therefore 
statistical analysis was performed only on groups containing 
intermediate and extensive metabolizers. Compared to group 
1 patients, the patients in group 2 were found to be older with 
significantly enlarged left atrial diameters (Table 1). No sta-
tistical difference was found in the measured ECG intervals 
(PR, QRS, QT) when compared among initial, 3 months and 
6 months follow-up visits. 
TABle 1. Patient characteristics
group i (n=12) group ii (n=14) p value
Male gender- n (%) 7 (58.3%) 10 (71.4%) 0.48
Age-years 47.25± 10.8 56.2± 10.8 0.04
Age group (n, %per arm)
<40 years old
41-59 years old
>60 years old
5 (41.7%)
4 (33.3%)
3 (25.0%)
2 (14.3%)
4 (28.6%)
8 (57.1%)
0.18
Smoking history –n (%) 2 (16.7) 6 (42.9) 0.14
Ethanol history –n (%) 2 (16.7) 2 (14.2) 0.86
AF Duration (years) 4.16±5.37 4.93±3.95 0.67
no. of AF Recurrences (past year)
<10 –n (%)
>10
7 (58.3)
5 (41.7)
8 (57.1)
6 (42.9)
0.95
duration of AF episodes
Minutes–n (%)
Hours
Days
Weeks
Months
5 (45.5)
3 (27.3)
2 (18.2)
1 (9.1)
0
2 (15.4)
5 (38.5)
3 (23.1)
0
3 (23.1)
0.21
Number of antiarrhythmic drugs 0.58±0.52 0.93±0.62 0.13
Number of cardioversions 0.75±1.38 1.14±1.41 0.44
Comorbidities
None–n (%)
Hypertension
Hyperlipidemia
9 (81.8)
1 (9.1)
1 (9.1)
9 (64.3)
4 (28.6)
1 (7.1)
0.482
Interventricular septum width (mm) 10.36±1.63 11.62±1.61 0.07
Left atrial diameter (mm) 35.08±3.92 40.36±5.73 0.01
Left ventricular ejection fraction (%) 60.0 59.29±1.86 0.18
Statins–n (%) 3 (25%) 2 (14.3%) 0.49
ACE inhibitors–n (%) 3 (25%) 3 (21.4%) 0.82
Beta blockers–n (%) 5 (41.7%) 6 (42.9%) 0.95
Coumadin–n (%) 0 4 (28.6%) 0.04
Aspirin–n (%) 8 (66.7%) 5 (35.7%) 0.11
ACE = angiotensin converting enzyme; AF = atrial fibrillation
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d i S C u S S i o n
It is well known that patients respond differently to the 
same medication. A favorable response occurs in only 30%-
70% of individuals, with a significant number of patients suf-
fering from severe adverse drug reactions. One of the benefits 
of pharmacogenomics is its potential to reduce adverse drug 
reactions. 13 Although numerous factors (age, sex, body weight, 
nutrition, comorbidities, medications, infections, and/or or-
gan function) can contribute to the variability seen in drug 
response, it is estimated that genetics may be one of the most 
important factors that accounts for 20-95% of the variability 
in drug disposition and effects. 
There are more than 30 families of drug-metabolizing 
enzymes in humans, and essentially all have genetic variants, 
many of which translate into functional changes in encoded 
proteins. These enzymes are divided into phase I (predomi-
nantly oxidative) and phase II (conjugative) categories. The 
cytochrome P450 (CYP) enzyme system is an example of a 
phase I system. 
Up to 23% of the population, depending on their ethnic 
background, has genetically determined differences in the 
metabolism of drugs by the CYP enzymes CYP2C9, CYP2C19, 
and CYP2D6.11 More than 50% of the clinically used drugs 
are cleared through the action of CYP enzymes; CYP2D6 and 
CYP3A4 metabolize the majority of these drugs.
Patients with lone atrial fibrillation were enrolled in this 
study. By exclusion criteria, these were healthy patients with-
out significant comorbidities except for hypertension. Prior 
studies have shown that drug metabolism can be influenced 
by the patient’s age, sex, and genetic profile. For example, a 
study by Doki et al revealed clinically relevant decrease in ef-
ficacy of flecainide among male, but not female, patients.16 In 
another study by the same authors, CYP2D6 genotype, as well 
as body weight, age, sex, and serum creatinine were shown to 
affect flecainide pharmacokinetics in Japanese patients with 
supraventricular arrhythmias.7 Therefore, in the present study, 
stringent exclusion criteria were applied for patient selection in 
an effort to minimize effects of any such factors on flecainide’s 
metabolism and efficacy. 
In a recently published review article, Wang et al discuss 
the issue of genomics and drug response.17 Specifically, they 
focus on cardiovascular drugs, warfarin and clopidogrel, as 
well as agents used for infectious disease and antineoplastic 
drugs. There are several prospective clinical trials investigating 
the value of this genetic information in patients on warfarin 
therapy.18
Tenneze et al studied the pharmacokinetics and elec-
trocadiographic effects of a new controlled-release form of 
flecainide and found that the CYP2D6 polymorphism did not 
appear to influence flecainide disposition kinetics or electro-
cardiographic effects in steady state.19 Martinez-Selles et al 
studied the pharmacogenetics of flecainide and propafenone 
in 40 patients with atrial fibrillation.20 They found 47% poor 
metabolizers and 53% extensive metabolizers. Antiarrhythmic 
treatment was effective in 67% of patients with no difference 
between poor and extensive metabolizers. Adverse effects were 
more frequent in the poor metabolizers.
In our study, 73% of patients were extensive metaboliz-
ers of flecainide. The CYP2D6 genotype of the patients did 
not correlate with drug efficacy or side-effects. Although 
more males than females were in the EM group, statistical 
significance was not reached (p=0.24). The most prevalent 
TABle 2. CYP2D6 Genotypes in 26 Patients with Lone AF
Phenotype (%) 
(Metabolizers)
genotype n  
(Male/Female)
efficacy of Flecainide 
(effective/n)
no. of patients with side 
effects
Ultra-rapid (UM) (3.8%) “1/2xN” 1 (1/0) 0/1 0/1
Extensive (EM)(73%) “1/41” 6 (4/2) 4/6 0/6
“1/4” 2 (1/1) 1/2 0/2
“1/1” 4 (2/2) 3/4 1/4
“1/2  ” 4 (3/1) 2/4 0/4
“2/4” 1 (0/1) 1/1 1/1
“2/2” 1 (1/0) 1/1 0/1
“2/17” 1 (1/0) 0/1 0/1
Intermediate (IM) (19%) “10/41” 2 (1/1) 1/2 0/2
“41/41” 1 (0/1) 1/1 1/1
“4/41” 2 (1/1) 2/2 1/2
Poor (PM) (3.8%) “4/4” 1 (1/0) 1/1 0/1
N.B.: the different genotypes are shown in quotes
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genotype was “1/41” which was found in 6/19 (31%) patients 
with an extensive metabolizer phenotype. In 4 out of these 6 
patients, flecainide was effective in preventing atrial fibrilla-
tion and did not cause side-effects. Clinically, 1 patient in the 
extensive metabolizers group benefitted from a higher dose 
of flecainide, 2 patients from the intermediate group and 1 
patient from the poor metabolizers group had side-effects and 
benefitted from a lower dose of flecainide. 
S T u d y  l i M i T A T i o n S
Flecainide blood levels were not processed in this study 
population. The correlation between blood levels of flecainide 
and the genetic profile could have further contributed to the 
understanding of the role of pharmacogenetics in this patient 
population. Although, according to a review article by Zhou, 
the large inter-individual variability in the pharmacokinetics 
of flecainide leads to poor correlation between daily dose and 
serum concentrations.3 Additionally, the population sample 
size in this study was small and therefore the results cannot 
be extrapolated to other populations.
C o n C l u S i o n
In this small series of patients with lone atrial fibrillation, 
most patients (73%) were found to be extensive metabolizers 
of flecainide. No statistically significant correlation was found 
between the patients’ genotype, flecainide efficacy or side 
effects. A larger scale study is required to clarify the clinical 
importance of the genetic profile in the treatment of patients 
with flecainide.
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